In Vitro and In Vivo Evaluation of Fluorescently Labeled Borocaptate-Containing Liposomes

摘要: Boron neutron capture therapy (BNCT), a binary cancer therapeutic modality, has moved to new phase since development of accelerator-based sources and establishment BNCT centers in Finland Japan. That stimulated efforts for better boron delivery agent development. As liposomes have shown effective properties sufficient tumor retention, fluorescent liposome labelling may serve as rapid method study initial ability newly synthesized be captured by cells prior experiments on accumulation irradiation. In this work, we studied the biodistribution pegylated with encapsulated borocaptate (BSH) label (Nile Red) U87 (human glioblastoma), SW-620 colon carcinoma), SK-MEL-28 melanoma), FetMSC (mesenchymal human embryo stem cells), EMBR (primary embryocytes) cell lines well an orthotopic xenograft model glioma SCID mice. Results indicate that microscopy is at determining intracellular localization using label. The synthesized, showed higher tumors compared normal cells, characteristic concentration peaks lines, provided vivo selectivity several-fold tissue fluorescence 6-h timepoint. Graphical abstract Fluorescent images U-87 after 24 hours incubation BSH-containing labeled lipophilic Nile Red (red color)and water-soluble FITC-Dextran (green color); nuclei blue color (DAPI-staining) (×400). Scale bar 50 μm. serves anexpress efficiency evaluation irradiation experiments.